comparemela.com

Latest Breaking News On - Lucid diagnostics - Page 1 : comparemela.com

Head to Head Analysis: Lucid Diagnostics (NASDAQ:LUCD) & Shockwave Medical (NASDAQ:SWAV)

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Shockwave Medical (NASDAQ:SWAV – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Volatility and Risk Lucid Diagnostics has a beta […]

California
United-states
New-york
Santa-clara
Pavmed-inc
Shockwave-medical-inc
Lucid-diagnostics-inc
Lucid-diagnostics
Get-free-report
Shockwave-medical
Given-lucid-diagnostic
Diagnostics-inc

Cantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Lucid Diagnostics Inc. (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Lucid Diagnostics in a report issued on Wednesday, May 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.06) per share for the year, down from their […]

United-states
Nasdaq
Lucid-diagnostics-inc
Needham-company
Cantor-fitzgerald
Lucid-diagnostics
Free-report
Lucid-diagnostic
Get-free-report
Diagnostics-stock-down
Diagnostics-inc

Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD)

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price objective on the stock. Separately, Cantor Fitzgerald reduced their price target on shares of Lucid Diagnostics from $3.80 to $3.00 […]

United-states
Lucid-diagnostics-inc
Cantor-fitzgerald
Needham-company
Lucid-diagnostics
Free-report
Diagnostics-stock-down
Get-free-report
Diagnostics-inc
Esoguard-esophageal
Esocheck-esophageal-cell

Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […]

United-states
Lucid-diagnostics-company-profile
Lucid-diagnostics-inc
Cantor-fitzgerald
Needham-company
Lucid-diagnostics
Free-report
Diagnostics-stock-down
Get-free-report
Diagnostics-inc
Esoguard-esophageal

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PAVmed Provides Business Update and First Quarter 2024 Financial Results
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Ohio
United-states
Lishan-aklog
Veris-health-inc
Veris-health
Pavmed-inc
Source-pavmed-inc
Portio-corp
Nasdaq
Lucid-diagnostics-inc
Prnewswire-pavmed-inc
National-cancer-institute
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.